Comparative bioavailability of levamisole in non lactating ewes and goats.
An original HPLC assay enabled the quantitation of levamisole in biological fluids of ewes (n = 4) and goats (n = 4). An open two compartment model showed the development of the drug in animals after oral (10 mg X kg -1) intramuscular (7.5), and subcutaneous (7.5) administrations by veterinary therapeutic forms. Greater efficiency was obtained in both species after intramuscular rather than subcutaneous or oral administrations. After intramuscular injection, levamisole levels in nasal secretion and saliva were five to 20 times higher than in plasma. Because of the high susceptibility of goats to levamisole, the subcutaneous route is preferred in this animal.
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001826:Body Fluids / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006041:Goats / Q000378:metabolism*; D007273:Injections, Intramuscular / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000662:veterinary; D007978:Levamisole / Q000008:administration & dosage / Q000378:metabolism*; D012756:Sheep / Q000378:metabolism*
D007978:Levamisole